131 related articles for article (PubMed ID: 22215532)
1. Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors.
Massard C; Salazar R; Armand JP; Majem M; Deutsch E; García M; Oaknin A; Fernández-García EM; Soto A; Soria JC
Invest New Drugs; 2012 Dec; 30(6):2318-26. PubMed ID: 22215532
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors.
Vilar E; Grünwald V; Schöffski P; Singer H; Salazar R; Iglesias JL; Casado E; Cullell-Young M; Baselga J; Tabernero J
Invest New Drugs; 2012 Feb; 30(1):299-305. PubMed ID: 20820909
[TBL] [Abstract][Full Text] [Related]
3. Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.
Schöffski P; Dumez H; Ruijter R; Miguel-Lillo B; Soto-Matos A; Alfaro V; Giaccone G
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1397-403. PubMed ID: 21465314
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
5. Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Baird RD; Kitzen J; Clarke PA; Planting A; Reade S; Reid A; Welsh L; López Lázaro L; de las Heras B; Judson IR; Kaye SB; Eskens F; Workman P; deBono JS; Verweij J
Mol Cancer Ther; 2009 Jun; 8(6):1430-7. PubMed ID: 19509256
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Massard C; Margetts J; Amellal N; Drew Y; Bahleda R; Stephens P; Armand JP; Calvert H; Soria JC; Coronado C; Kahatt C; Alfaro V; Siguero M; Fernández-Teruel C; Plummer R
Invest New Drugs; 2013 Jun; 31(3):623-30. PubMed ID: 22688291
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.
Salazar R; Cortés-Funes H; Casado E; Pardo B; López-Martín A; Cuadra C; Tabernero J; Coronado C; García M; Soto Matos-Pita A; Miguel-Lillo B; Cullell-Young M; Iglesias Dios JL; Paz-Ares L
Cancer Chemother Pharmacol; 2013 Jul; 72(1):75-83. PubMed ID: 23645288
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
12. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
14. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Taamma A; Misset JL; Riofrio M; Guzman C; Brain E; Lopez Lazaro L; Rosing H; Jimeno JM; Cvitkovic E
J Clin Oncol; 2001 Mar; 19(5):1256-65. PubMed ID: 11230466
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
17. A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
Capdevila J; Clive S; Casado E; Michie C; Piera A; Sicart E; Carreras MJ; Coronado C; Kahatt C; Soto Matos-Pita A; Fernandez Teruel C; Siguero M; Cullell-Young M; Tabernero J
Cancer Chemother Pharmacol; 2013 May; 71(5):1247-54. PubMed ID: 23455428
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK
Invest New Drugs; 2012 Feb; 30(1):316-26. PubMed ID: 20839029
[TBL] [Abstract][Full Text] [Related]
19. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.
Gelmon K; Hirte H; Fisher B; Walsh W; Ptaszynski M; Hamilton M; Onetto N; Eisenhauer E
Invest New Drugs; 2004 Aug; 22(3):263-75. PubMed ID: 15122073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
